Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria

Expert Review of Anti-Infective Therapy

Volumn 17, Issue 5, 2019, Pages 307-309

  Jean, Shio Shin ^a,b   Hsueh, Shun Chung ^c   Lee, Wen Sen ^a   Hsueh, Po Ren ^d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFIDEROCOL; CEFTAZIDIME; CLAVULANIC ACID; COLISTIN; IMIPENEM; SULBACTAM; TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MECHANISM; EDITORIAL; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; ANIMAL; DRUG EFFECT; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 85065438562     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2019.1612240     Document Type: Editorial

References (15)

1. Jean SS, Lee WS, Lam C, et al. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol. 2015;10:407–425.
2. Jean SS, Hsueh PR., Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008-14: results from the study for monitoring antimicrobial resistance trends (SMART). J Antimicrob Chemother. 2017;72:166–171.
3. Lee CR, Lee JH, Park KS, et al. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol. 2016;7:895.
4. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–327.
5. Avery LM, Nicolau DP. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opin Investig Drugs. 2018;27:325–338.
6. Domalaon R, Idowu T, Zhanel GG, et al. Antibiotic hybrids: the next generation of agents and adjuvants against Gram-negative pathogens? Clin Microbiol Rev. 2018;31:e00077–17.
7. Ghazi IM, Monogue ML, Tsuji M, et al. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents. 2018;51:206–212.
8. Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–1328.
9. Dobias J, Dénervaud-Tendon V, Poirel L, et al. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36:2319–2327.
10. Hsueh SC, Lee YJ, Huang YT, et al. In vitro activities of cefiderocol, ceftolozane/ tazobactam,ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019;74:380–386.
11. Monogue ML, Tsuji M, Yamano Y, et al. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61:e01022–17.
12. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing. M100-ED29. Wayne, PA: CLSI; 2019.
13. Katsube T, Wajima T, Ishibashi T, et al. Pharmacokinetic/Pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother. 2016;61:e01381–16.
14. Matsunaga Y, Echols R, Katsube T, et al. Cefiderocol (S-649266) for nosocomial pneumonia caused by gram-negative pathogens: study design of APEKS-NP, a phase 3 double-blind parallel-group randomized clinical trial. Am J Respir Crit Care Med. 2018 [cited 2019 Jan2];197:A3290. Available from: https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A3290
15. Matsumoto S, Singley CM, Hoover J, et al. Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother. 2017;61:e00700–17.